Market Overview

Colorectal Cancer (CRC) Drugs/ Therapeutic Market 2016-2022 - Analysis Report by Drug Class (Chemotherapy, Immunotherapy), Country And Segment Forecasts -


The "Colorectal
Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis
Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S.,
U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016
- 2022"
report has been added to's

The global colorectal cancer (CRC) drugs market size is expected to
reach USD 10.8 billion by 2022, exhibiting a CAGR of 3.3% during the
forecast period

Several factors such as increasing target population and rising adoption
of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of
the colorectal cancer (CRC) market. If approved, Array Biopharma's
cetuximab plus encorafenib would become the first therapy indicated for
BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer
stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of
high-risk resectable colorectal cancer. Lack of pipeline agents in this
setting presents a good opportunity for development of effective
treatments that can improve cure rates for resected patients. At
present, most available treatments for resectable CRC include cheaper
chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin,
Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar
penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar
approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and
Krabeva are some of the biosimilars to Avastin launched in India.
Several other biosimilars to Avastin and Erbitux are under development.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Colorectal Cancer Drugs Market Overview

Chapter 5 Colorectal Cancer Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

Companies Mentioned

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck
  • Roche
  • Sanofi

For more information about this report visit

View Comments and Join the Discussion!